Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals Plc on May 30, 2014. The report discloses a specific corporate governance event regarding the departure of a senior executive.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to personnel changes and does not contain financial statements.
Material Changes
The material change reported is the resignation of Fintan Keegan from his position as Executive Vice President, Technical Operations. His resignation is effective as of August 11, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the executive departure.
Key Facts for Investors
- Fintan Keegan is resigning as Executive Vice President, Technical Operations.
- The resignation becomes effective on August 11, 2014.
- The report was signed by Suzanne Sawochka Hooper, Executive Vice President and General Counsel, on June 4, 2014.